[
  {
    "ts": null,
    "headline": "Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out",
    "summary": "Shares of Apogee Therapeutics have gained 34% over the past two days as the small biotech looks to take on Regeneron and Sanofi.",
    "url": "https://finnhub.io/api/news?id=1bc91aebe063519e3f473d0ae40b4d2200fb144014dfde8923a8893b6687f52b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760029429,
      "headline": "Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out",
      "id": 137033529,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Shares of Apogee Therapeutics have gained 34% over the past two days as the small biotech looks to take on Regeneron and Sanofi.",
      "url": "https://finnhub.io/api/news?id=1bc91aebe063519e3f473d0ae40b4d2200fb144014dfde8923a8893b6687f52b"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=ca82ab799119c8b675ad8dfb32708bd909253fdcc15fdb852c7318f1d1f1e1d4",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760028360,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 137083655,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=ca82ab799119c8b675ad8dfb32708bd909253fdcc15fdb852c7318f1d1f1e1d4"
    }
  },
  {
    "ts": null,
    "headline": "GSK's Hidden Growth Engines Beyond HIV And Oncology",
    "summary": "GSK plcâs strong oncology growth, highlighted by Ojjaara sales and an upgraded 2025 outlook, earns a continued 'Buy' rating. Learn more about GSK stock here.",
    "url": "https://finnhub.io/api/news?id=ee4aebd4250ddb46bf7735456b5f1abe9d3ddd42dfabc80b324a2accb000cca8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760016130,
      "headline": "GSK's Hidden Growth Engines Beyond HIV And Oncology",
      "id": 137032881,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1193052383/image_1193052383.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "GSK plcâs strong oncology growth, highlighted by Ojjaara sales and an upgraded 2025 outlook, earns a continued 'Buy' rating. Learn more about GSK stock here.",
      "url": "https://finnhub.io/api/news?id=ee4aebd4250ddb46bf7735456b5f1abe9d3ddd42dfabc80b324a2accb000cca8"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo",
    "summary": "REGN secures FDA approval to expand Libtayo's label for high-risk skin cancer, boosting its oncology momentum amid Eylea sales pressure.",
    "url": "https://finnhub.io/api/news?id=39447889a32bc7c16b2a500dd4cb0e7c75c3b4489c2cec4e92e325f25176f562",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760015700,
      "headline": "Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo",
      "id": 137033530,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "REGN secures FDA approval to expand Libtayo's label for high-risk skin cancer, boosting its oncology momentum amid Eylea sales pressure.",
      "url": "https://finnhub.io/api/news?id=39447889a32bc7c16b2a500dd4cb0e7c75c3b4489c2cec4e92e325f25176f562"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron, needing a turnaround, gains new use for cancer drug",
    "summary": "Libtayo’s latest approval for a type of skin cancer should boost future sales, according to one analyst, but doesn’t have the “broad-reaching implications” for Regeneron's Eylea franchise investors had hoped.",
    "url": "https://finnhub.io/api/news?id=6188aaabab6d5940c2a92cadd7af0815169ba7709d50ea460891095858e36c9d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760008980,
      "headline": "Regeneron, needing a turnaround, gains new use for cancer drug",
      "id": 137033531,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Libtayo’s latest approval for a type of skin cancer should boost future sales, according to one analyst, but doesn’t have the “broad-reaching implications” for Regeneron's Eylea franchise investors had hoped.",
      "url": "https://finnhub.io/api/news?id=6188aaabab6d5940c2a92cadd7af0815169ba7709d50ea460891095858e36c9d"
    }
  },
  {
    "ts": null,
    "headline": "Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab",
    "summary": "The bispecific antibodies market presents key opportunities in oncology, autoimmune, and infectious diseases, driven by rapid technological advancements and strategic collaborations. Regional manufacturing and diverse supplier networks optimize supply chains, while innovation in antibody structures supports tailored therapies. Bispecific Antibodies Market Bispecific Antibodies Market Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The \"Bispecific Antibodies Market - Global Forecast 2025-2032\" report h",
    "url": "https://finnhub.io/api/news?id=d1948cb61301d64f144bdf4db2d55b6472eca18c5b1637ffc6ab4dc18bf7a5a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759998180,
      "headline": "Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab",
      "id": 137029703,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The bispecific antibodies market presents key opportunities in oncology, autoimmune, and infectious diseases, driven by rapid technological advancements and strategic collaborations. Regional manufacturing and diverse supplier networks optimize supply chains, while innovation in antibody structures supports tailored therapies. Bispecific Antibodies Market Bispecific Antibodies Market Dublin, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The \"Bispecific Antibodies Market - Global Forecast 2025-2032\" report h",
      "url": "https://finnhub.io/api/news?id=d1948cb61301d64f144bdf4db2d55b6472eca18c5b1637ffc6ab4dc18bf7a5a4"
    }
  }
]